MBMarisa A. Bittoni

Marisa A. Bittoni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marisa A. Bittoni has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Randall E. Harris

    Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA

    2 shared publications
  • Steven K. Clinton

    The Ohio State University, College of Medicine, Division of Medical Oncology, Columbus, OH, United States; The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States

    2 shared publications
  • Brian C. Focht

    Department of Human Sciences/Kinesiology, The Ohio State University College of Education and Human Ecology, Columbus, OH, USA

    1 shared publication
  • Christopher Alan Taylor

    The Ohio State University

    1 shared publication
  • Colleen K. Spees

    The Ohio State University, College of Medicine, Division of Health Sciences and Medical Dietetics, Columbus, OH, United States; The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States

    1 shared publication
  • David P. Carbone

    Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA

    1 shared publication

Latest Publications

  • Open Access

    Ibuprofen and fatal lung cancer: A brief report of the prospective results from the Third National Health and Nutrition Examination Survey (NHANES III)

    by Marisa A. Bittoni, David P. Carbone, Randall E. Harris

    Chronic inflammation appears to increase the risk of lung cancer and, reciprocally, agents that reduce inflammation have been found to reduce this risk. However, few prospective studies have assessed whether there exists an association between lung cancer and the use of non-steroidal anti-inflammatory drugs (NSAIDs). In the present study, the association between fatal lung cancer and NSAIDs was investigated using cohort data from the Third National Health and Nutrition Examination Study (NHANES III). Baseline data were collected on smoking, NSAID use and other lifestyle factors for 10,735 participants during 1988–1994, with cause-specific mortality status ascertained through probabilistic record matching based on the National Death Index until 2006. Cox proportional hazards regression models were conducted to estimate hazard ratios (HRs) and confidence intervals (CIs) for NSAID use and death from lung cancer, controlling for current smoking and other covariates. During the 18 years of follow-up, 269 participants succumbed to lung cancer, of whom 252 (93.6%) reported a history of cigarette smoking. Since all but 17 of the 269 fatal lung cancer cases occurred among current or former smokers, estimates of NSAID effects were ascertained from a sub-cohort of 5,882 individuals who reported a history of past or current cigarette smoking. Multivariate regression models revealed that regular use of ibuprofen resulted in a 48% reduced risk of lung cancer mortality (HR=0.52, 95% CI: 0.33–0.82, P<0.01). The main effects of other compounds tested, such as aspirin or acetaminophen, were not statistically significant. Our results suggest that high-risk subgroups of smokers may benefit from the regular use of specific NSAIDs, which may prove to be a useful strategy for lung cancer prevention.


  • Trends in mastectomy rates over time in elderly women with stage I, hormone-sensitive breast cancer: A SEER-based study.

    by Jose G. Bazan, Marisa A Bittoni, James L Fisher, Julia R. White

    1063 Background: Randomized trials and registry data established that breast conservation with lumpectomy (Lump) and breast radiotherapy (RT) yields equivalent cancer outcomes to mastectomy (Mast) for women with early stage breast cancer (BC). Clinical trial data since 2004 increasingly supports that Lump alone compared to Lump+breast RT results in equivalent survival and acceptable cancer control in women ≥ 70 years old with stage I (T1N0) hormone-sensitive (HS) BC on endocrine therapy. Since Lump alone represents sufficient treatment for elderly women with stage I HS BC we hypothesize that Mast rates have decreased in this subgroup. Methods: We used the Surveillance Epidemiology and End Results (SEER) registry data to conduct this study. We included women ≥ 70 years old with T1N0 HS BC classified as ER+ or PR+ from 2000-2012. We compared rates of Mast and Lump (+/-RT) in women diagnosed before 2004 to those diagnosed from 2005-2012. We also examined Lump and Mast rates by race: White, Black, and Asian-Pacific-Islander(API). Statistical analyses were performed using differences in proportions (p < 0.05 considered statistically significant). Results: 87,009 women met the inclusion criteria (N = 30,050 before 2004; N = 56,959 from 2005-2012). Since 2004, Mast rates decreased by 5.2% (95% CI, 4.5%-5.9%) from 32.6% to 27.4% (p < 0.0001). Lump rates increased by 3.4% (95% CI, 2.8%-4.1%) from 66.4% to 69.8% (p < 0.0001). Before 2004, elderly white women were more likely to undergo Lump compared to black (66.8% vs. 62.6%, p = 0.0421) or API women (66.8% vs. 61.6%, p < 0.0001) and less likely to undergo Mast compared to black (32.3% vs. 34.9%, p < 0.0001) or API (32.3% vs. 38.0%, p < 0.0001) women. Since 2004, elderly white women remained least likely to undergo Mast in comparison to black women (26.8% vs. 30.8%, p < 0.0001) or API women (26.8% vs. 33.6%, p < 0.0001). Conclusions: We found a modest decrease in Mast rates in elderly women with stage I HS BC since 2004. However, more than 25% of women in this subgroup continue to undergo Mast. Mast rates are higher in elderly black and API women compared to white women. Further study is warranted to understand why Mast rates did not decline more in this favorable risk population.


  • Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey

    by Marisa A. Bittoni, Brian C. Focht, Steven K. Clinton, Janet Buckworth, Randall E. Harris

    Chronic inflammation plays an important role in lung carcinogenesis. Few prospective studies have examined associations between lung cancer, serum C-reactive protein (CRP), a measure of systemic inflammation, and inflammatory lifestyle factors, such as smoking and obesity. This study prospectively examined the relationship between CRP and lung cancer death and its interrelationships with several lifestyle factors. Baseline data on smoking and other lifestyle variables were collected for 8,950 participants in the Third National Health and Nutrition Examination Survey (NHANES III: 1988-1994). Baseline CRP levels were measured in serum samples by nephelometry. Mortality status was ascertained through probabilistic record matching using the National Death Index through 2006. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) for CRP and lung cancer death, with adjustment for smoking and other variables. During 18 years of follow-up, 219 individuals died from lung cancer. Multivariate regression models revealed a dose-response effect for elevated CRP and risk of lung cancer death when adjusting for age, gender, BMI and smoking. Compared to individuals with CRP 7 mg/l, P-trend <0.0001). The risk of lung cancer death for smokers increased 9-fold in adjusted models (P<0.0001). When stratified by gender and smoking status the effects of CRP were similar for smokers and males but did not reach statistical significance for females and non-smokers. This study supports a dose-dependent relationship between lung cancer death and CRP for males and smokers, but additional efforts are needed to better elucidate these relationships in women and non-smokers. The results suggest that CRP may emerge as a valuable tool in identifying high-risk subgroups of smokers for lung cancer prevention strategies.


  • Open Access

    Assessment of the Effects of Severe Obesity and Lifestyle Risk Factors On Stage of Endometrial Cancer

    by Marisa A. Bittoni, James L. Fisher, Jeffrey M. Fowler, George L. Maxwell, Electra D. Paskett

    Background: Lifestyle risk factors, including obesity, have been associated with increased risk of endometrial cancer (EC). Women with higher obesity levels tend to have less aggressive EC disease stage and histology. This study further investigated associations between nonmodifiable risk factors, such as age, race, and grade, and modifiable lifestyle factors, such as diet and physical activity expenditure, in relation to severe obesity and late versus early EC stage at diagnosis. Methods: Demographic, anthropometric, and lifestyle surveys were administered to 177 women with histologically confirmed EC. Logistic regression analyses assessed the relationship between obesity and other risk factors on EC stage at diagnosis. Results: In multivariate models, body mass index (BMI) < 35 was not significantly associated with late EC stage at diagnosis (OR = 1.67, P = 0.219) when adjusting for grade and age. Grade was significantly associated with EC stage when controlling for BMI and age (OR = 8.48, P = .000). Women more than the age of 60 had a fourfold increased risk of diagnosis at late versus early EC stage when adjusting for other risk factors. Age had a confounding effect on the obesity-EC stage association. Conclusions: Our results corroborate those of past studies showing that BMI is not an independent risk factor for EC stage and that age may have confounded the obesity-EC stage association. Because of mixed results and implications for treatment outcomes, however, further research examining these variables is warranted. Impact: Our results provide further insight into the obesity EC-stage association, especially the confounding effect of age. Future studies should examine modifiable lifestyle factors in larger and more diverse populations. Cancer Epidemiol Biomarkers Prev; 22(1); 76–81. ©2012 AACR.